{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T05:59:37Z","timestamp":1784872777318,"version":"3.55.0"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,5]],"date-time":"2025-07-05T00:00:00Z","timestamp":1751673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,5]],"date-time":"2025-07-05T00:00:00Z","timestamp":1751673600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Major and Key Projects Jointly Constructed by Henan Province and Ministry of Science and Technology","award":["SBGJ202302014"],"award-info":[{"award-number":["SBGJ202302014"]}]},{"name":"Major and Key Projects Jointly Constructed by Henan Province and Ministry of Science and Technology","award":["SBGJ202101003"],"award-info":[{"award-number":["SBGJ202101003"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82371864"],"award-info":[{"award-number":["82371864"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100006407","name":"Natural Science Foundation of Henan Province","doi-asserted-by":"crossref","award":["232300421121"],"award-info":[{"award-number":["232300421121"]}],"id":[{"id":"10.13039\/501100006407","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-07318-6","type":"journal-article","created":{"date-parts":[[2025,7,5]],"date-time":"2025-07-05T03:08:12Z","timestamp":1751684892000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Unraveling novel variants in the NF1 gene and investigating potential therapeutic strategies"],"prefix":"10.1038","volume":"15","author":[{"given":"Jianmei","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaoping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinrui","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenke","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaodong","family":"Huo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongjie","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinming","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yibing","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shixiu","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,5]]},"reference":[{"key":"7318_CR1","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1038\/s41591-018-0263-8","volume":"25","author":"F D\u2019Angelo","year":"2018","unstructured":"D\u2019Angelo, F. et al. The molecular landscape of glioma in patients with Neurofibromatosis 1. Nat. Med. 25, 176\u2013187 (2018).","journal-title":"Nat. Med."},{"key":"7318_CR2","doi-asserted-by":"publisher","first-page":"1331278","DOI":"10.3389\/fgene.2024.1331278","volume":"15","author":"MM Mudau","year":"2024","unstructured":"Mudau, M. M. et al. Mutation analysis and clinical profile of South African patients with Neurofibromatosis type 1 (NF1) phenotype. Front. Genet. 15, 1331278 (2024).","journal-title":"Front. Genet."},{"key":"7318_CR3","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.semcdb.2016.02.007","volume":"52","author":"E Rad","year":"2016","unstructured":"Rad, E. & Tee, A. R. Neurofibromatosis type 1: Fundamental insights into cell signalling and cancer. Semin Cell Dev. Biol. 52, 39\u201346 (2016).","journal-title":"Semin Cell Dev. Biol."},{"key":"7318_CR4","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1002\/humu.22832","volume":"36","author":"K Rojnueangnit","year":"2015","unstructured":"Rojnueangnit, K. et al. High incidence of noonan syndrome features including short stature and pulmonic stenosis in patients carrying NF1 missense mutations affecting p.Arg1809: Genotype-phenotype correlation. Hum Mutat 36, 1052\u20131063 (2015).","journal-title":"Hum Mutat"},{"key":"7318_CR5","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/S0092-8674(01)00245-8","volume":"104","author":"Karen Cichowski","year":"2001","unstructured":"Karen Cichowski, & Jacks, T. NF1 Tumor suppressor gene function: Narrowing the GAP. Cell 104, 593\u2013604 (2001).","journal-title":"Cell"},{"key":"7318_CR6","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1038\/s42003-023-04815-0","volume":"6","author":"J Baez-Flores","year":"2023","unstructured":"Baez-Flores, J., Rodriguez-Martin, M. & Lacal, J. The therapeutic potential of neurofibromin signaling pathways and binding partners. Commun. Biol. 6, 436 (2023).","journal-title":"Commun. Biol."},{"issue":"11","key":"7318_CR7","doi-asserted-by":"publisher","first-page":"2365","DOI":"10.3390\/cells9112365","volume":"9","author":"M Bergoug","year":"2020","unstructured":"Bergoug, M. et al. Neurofibromin Structure, Functions and Regulation. Cells 9(11), 2365 (2020).","journal-title":"Cells"},{"key":"7318_CR8","first-page":"5636","volume":"27","author":"A Amato","year":"2023","unstructured":"Amato, A., Imbimbo, B. P. & Falsini, B. Neurofibromatosis type 1-associated optic pathway gliomas: Pathogenesis and emerging treatments. Eur. Rev. Med. Pharmacol. Sci. 27, 5636\u20135653 (2023).","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"7318_CR9","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1093\/neuonc\/noac146","volume":"24","author":"MJ Fisher","year":"2022","unstructured":"Fisher, M. J. et al. Management of neurofibromatosis type 1-associated plexiform neurofibromas. Neuro. Oncol. 24, 1827\u20131844 (2022).","journal-title":"Neuro. Oncol."},{"key":"7318_CR10","doi-asserted-by":"publisher","first-page":"2550","DOI":"10.1056\/NEJMoa1605943","volume":"375","author":"E Dombi","year":"2016","unstructured":"Dombi, E. et al. Activity of selumetinib in neurofibromatosis type 1-related plexiform neurofibromas. N. Engl. J. Med. 375, 2550\u20132560 (2016).","journal-title":"N. Engl. J. Med."},{"key":"7318_CR11","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1016\/j.mcna.2019.07.004","volume":"103","author":"KI Ly","year":"2019","unstructured":"Ly, K. I. & Blakeley, J. O. The diagnosis and management of neurofibromatosis type 1. Med. Clin. North. Am. 103, 1035\u20131054 (2019).","journal-title":"Med. Clin. North. Am."},{"key":"7318_CR12","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/s41586-021-03580-6","volume":"594","author":"Y Pan","year":"2021","unstructured":"Pan, Y. et al. NF1 mutation drives neuronal activity-dependent initiation of optic glioma. Nature 594, 277\u2013282 (2021).","journal-title":"Nature"},{"key":"7318_CR13","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1007\/s11523-024-01078-5","volume":"19","author":"N Somaiah","year":"2024","unstructured":"Somaiah, N., Paudyal, B., Winkler, R. E., Van Tine, B. A. & Hirbe, A. C. Malignant peripheral nerve sheath tumor, a heterogeneous, aggressive cancer with diverse biomarkers and no targeted standard of care: Review of the literature and ongoing investigational agents. Target Oncol. 19, 665\u2013678 (2024).","journal-title":"Target Oncol."},{"key":"7318_CR14","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1007\/s00381-020-04687-3","volume":"36","author":"E Martin","year":"2020","unstructured":"Martin, E., Flucke, U. E., Coert, J. H. & van Noesel, M. M. Treatment of malignant peripheral nerve sheath tumors in pediatric NF1 disease. Childs Nerv Syst 36, 2453\u20132462 (2020).","journal-title":"Childs Nerv Syst"},{"issue":"4","key":"7318_CR15","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.3390\/cancers15041217","volume":"15","author":"C Peduto","year":"2023","unstructured":"Peduto, C. et al. Neurofibromatosis Type 1: Pediatric aspects and review of genotype-phenotype correlations. Cancers 15(4), 1217 (2023).","journal-title":"Cancers"},{"key":"7318_CR16","first-page":"1978","volume":"24","author":"D Angelova-Toshkina","year":"2022","unstructured":"Angelova-Toshkina, D. et al. Neurofibromatosis type 1: A comparison of the 1997 NIH and the 2021 revised diagnostic criteria in 75 children and adolescents. Gen. Med. Off. J. Am. Coll. Med. Gen. 24, 1978\u20131985 (2022).","journal-title":"Gen. Med. Off. J. Am. Coll. Med. Gen."},{"key":"7318_CR17","first-page":"1506","volume":"23","author":"E Legius","year":"2021","unstructured":"Legius, E. et al. Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation. Gen. Med. Off. J. Am. Coll. Med. Gen. 23, 1506\u20131513 (2021).","journal-title":"Gen. Med. Off. J. Am. Coll. Med. Gen."},{"issue":"6","key":"7318_CR18","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.3390\/cancers16061119","volume":"16","author":"S Rana","year":"2024","unstructured":"Rana, S. et al. A systematic review of diagnostic modalities and strategies for the assessment of complications in adult patients with neurofibromatosis type 1. Cancers 16(6), 1119 (2024).","journal-title":"Cancers"},{"key":"7318_CR19","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1080\/14728222.2018.1465931","volume":"22","author":"JA Walker","year":"2018","unstructured":"Walker, J. A. & Upadhyaya, M. Emerging therapeutic targets for neurofibromatosis type 1. Expert Opin. Ther. Targets 22, 419\u2013437 (2018).","journal-title":"Expert Opin. Ther. Targets"},{"key":"7318_CR20","first-page":"405","volume":"17","author":"S Richards","year":"2015","unstructured":"Richards, S. et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Gen. Med. Off. J. Am. Coll. Med. Gen. 17, 405\u2013424 (2015).","journal-title":"Gen. Med. Off. J. Am. Coll. Med. Gen."},{"key":"7318_CR21","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1038\/s41388-021-02156-y","volume":"41","author":"J Mo","year":"2022","unstructured":"Mo, J., Moye, S. L., McKay, R. M. & Le, L. Q. Neurofibromin and suppression of tumorigenesis: beyond the GAP. Oncogene 41, 1235\u20131251 (2022).","journal-title":"Oncogene"},{"key":"7318_CR22","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1016\/j.jid.2023.01.043","volume":"143","author":"SD Rhodes","year":"2023","unstructured":"Rhodes, S. D. et al. RAS signaling gone awry in the skin: The complex role of RAS in cutaneous neurofibroma pathogenesis, emerging biological insights. J. Investig. Dermatol. 143, 1358\u20131368 (2023).","journal-title":"J. Investig. Dermatol."},{"key":"7318_CR23","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/j.ajhg.2009.03.010","volume":"84","author":"HV Firth","year":"2009","unstructured":"Firth, H. V. et al. DECIPHER: Database of chromosomal imbalance and phenotype in humans using ensembl resources. Am. J. Human Gen. 84, 524\u2013533 (2009).","journal-title":"Am. J. Human Gen."},{"key":"7318_CR24","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.1589","volume":"14","author":"Z Wang","year":"2024","unstructured":"Wang, Z. et al. Safety, pharmacokinetics and efficacy of selumetinib in Chinese adult and paediatric patients with neurofibromatosis type 1 and inoperable plexiform neurofibromas: The primary analysis of a phase 1 open-label study. Clin. Transl. Med. 14, e1589 (2024).","journal-title":"Clin. Transl. Med."},{"key":"7318_CR25","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/S1470-2045(19)30277-3","volume":"20","author":"J Fangusaro","year":"2019","unstructured":"Fangusaro, J. et al. Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial. Lancet Oncol. 20, 1011\u20131022 (2019).","journal-title":"Lancet Oncol."},{"key":"7318_CR26","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.1093\/neuonc\/noac109","volume":"24","author":"AM Gross","year":"2022","unstructured":"Gross, A. M. et al. Selumetinib in children with neurofibromatosis type 1 and asymptomatic inoperable plexiform neurofibroma at risk for developing tumor-related morbidity. Neuro Oncol. 24, 1978\u20131988 (2022).","journal-title":"Neuro Oncol."},{"key":"7318_CR27","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1056\/NEJMoa1912735","volume":"382","author":"AM Gross","year":"2020","unstructured":"Gross, A. M. et al. Selumetinib in children with inoperable plexiform neurofibromas. N Engl. J. Med. 382, 1430\u20131442 (2020).","journal-title":"N Engl. J. Med."},{"issue":"15","key":"7318_CR28","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1056\/NEJMoa1912735","volume":"382","author":"AM Gross","year":"2020","unstructured":"Gross, A. M. et al. Selumetinib in Children with Inoperable Plexiform Neurofibromas. N Engl. J. Med. 382(15), 1430\u20131442 (2020).","journal-title":"N Engl. J. Med."},{"key":"7318_CR29","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1007\/s11060-020-03443-6","volume":"147","author":"V Esp\u00edrito Santo","year":"2020","unstructured":"Esp\u00edrito Santo, V. et al. Selumetinib for plexiform neurofibromas in neurofibromatosis type 1: a single-institution experience. J. Neurooncol. 147, 459\u2013463 (2020).","journal-title":"J. Neurooncol."},{"key":"7318_CR30","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1093\/neuonc\/noad086","volume":"25","author":"AM Gross","year":"2023","unstructured":"Gross, A. M. et al. Long-term safety and efficacy of selumetinib in children with neurofibromatosis type 1 on a phase 1\/2 trial for inoperable plexiform neurofibromas. Neuro Oncol. 25, 1883\u20131894 (2023).","journal-title":"Neuro Oncol."},{"key":"7318_CR31","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1038\/s41591-024-03361-4","volume":"31","author":"AM Gross","year":"2025","unstructured":"Gross, A. M. et al. Selumetinib in adults with NF1 and inoperable plexiform neurofibroma: a phase 2 trial. Nat. Med. 31, 105\u2013115 (2025).","journal-title":"Nat. Med."},{"key":"7318_CR32","doi-asserted-by":"publisher","first-page":"2352","DOI":"10.1093\/neuonc\/noae121","volume":"26","author":"H Kim","year":"2024","unstructured":"Kim, H. et al. Safety and efficacy of selumetinib in pediatric and adult patients with neurofibromatosis type 1 and plexiform neurofibroma. Neuro Oncol. 26, 2352\u20132363 (2024).","journal-title":"Neuro Oncol."},{"key":"7318_CR33","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1186\/s12916-023-02927-2","volume":"21","author":"X Hu","year":"2023","unstructured":"Hu, X. et al. Phase 1 dose-escalation study to evaluate the safety, tolerability, pharmacokinetics, and anti-tumor activity of FCN-159 in adults with neurofibromatosis type 1-related unresectable plexiform neurofibromas. BMC Med. 21, 230 (2023).","journal-title":"BMC Med."},{"key":"7318_CR34","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1172\/JCI60578","volume":"123","author":"WJ Jessen","year":"2013","unstructured":"Jessen, W. J. et al. MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors. J. Clin. Investig. 123, 340\u2013347 (2013).","journal-title":"J. Clin. Investig."},{"key":"7318_CR35","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1200\/JCO.20.02220","volume":"39","author":"BD Weiss","year":"2021","unstructured":"Weiss, B. D. et al. NF106: A neurofibromatosis clinical trials consortium phase II trial of the MEK inhibitor mirdametinib (PD-0325901) in adolescents and adults with NF1-related plexiform neurofibromas. J. Clin. Oncol. 39, 797\u2013806 (2021).","journal-title":"J. Clin. Oncol."},{"key":"7318_CR36","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1200\/JCO.24.01034","volume":"43","author":"CL Moertel","year":"2025","unstructured":"Moertel, C. L. et al. ReNeu: A pivotal, phase IIb trial of mirdametinib in adults and children with symptomatic neurofibromatosis type 1-associated plexiform neurofibroma. J Clin Oncol 43, 716\u2013729 (2025).","journal-title":"J Clin Oncol"},{"key":"7318_CR37","doi-asserted-by":"publisher","first-page":"4946","DOI":"10.1126\/sciadv.adk4946","volume":"10","author":"KY Sarin","year":"2024","unstructured":"Sarin, K. Y. et al. Effect of NFX-179 MEK inhibitor on cutaneous neurofibromas in persons with neurofibromatosis type 1. Sci. Adv. 10, 4946 (2024).","journal-title":"Sci. Adv."},{"key":"7318_CR38","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/s11523-022-00888-9","volume":"17","author":"T Trippett","year":"2022","unstructured":"Trippett, T. et al. Cobimetinib in pediatric and young adult patients with relapsed or refractory solid tumors (iMATRIX-cobi): A multicenter, phase I\/II study. Target Oncol 17, 283\u2013293 (2022).","journal-title":"Target Oncol"},{"key":"7318_CR39","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s11060-024-04624-3","volume":"167","author":"E Lalancette","year":"2024","unstructured":"Lalancette, E. et al. Impact of trametinib on the neuropsychological profile of NF1 patients. J. Neurooncol. 167, 447\u2013454 (2024).","journal-title":"J. Neurooncol."},{"issue":"18","key":"7318_CR40","doi-asserted-by":"publisher","first-page":"4513","DOI":"10.3390\/cancers14184513","volume":"14","author":"LL Ge","year":"2022","unstructured":"Ge, L. L., Xing, M. Y., Zhang, H. B. & Wang, Z. C. Neurofibroma development in neurofibromatosis type 1: Insights from cellular origin and schwann cell lineage development. Cancers 14(18), 4513 (2022).","journal-title":"Cancers"},{"key":"7318_CR41","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1016\/j.jaad.2020.07.105","volume":"84","author":"BN Wilson","year":"2021","unstructured":"Wilson, B. N., John, A. M., Handler, M. Z. & Schwartz, R. A. Neurofibromatosis type 1: New developments in genetics and treatment. J. Am. Acad. Dermatol. 84, 1667\u20131676 (2021).","journal-title":"J. Am. Acad. Dermatol."},{"issue":"12","key":"7318_CR42","doi-asserted-by":"publisher","first-page":"63824","DOI":"10.1002\/ajmg.a.63824","volume":"194","author":"C Chelleri","year":"2024","unstructured":"Chelleri, C. et al. Novel causative variants in Legius syndrome: SPRED1 Genotype spectrum expansion. Am. J. Med. Gen. Part A 194(12), 63824 (2024).","journal-title":"Am. J. Med. Gen. Part A"},{"key":"7318_CR43","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1001\/jama.2009.1663","volume":"302","author":"L Messiaen","year":"2009","unstructured":"Messiaen, L. et al. Clinical and mutational spectrum of neurofibromatosis type 1-like syndrome. JAMA 302, 2111\u20132118 (2009).","journal-title":"JAMA"},{"key":"7318_CR44","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.ajhg.2017.12.001","volume":"102","author":"M Koczkowska","year":"2018","unstructured":"Koczkowska, M. et al. Genotype-phenotype correlation in NF1: Evidence for a more severe phenotype associated with missense mutations affecting NF1 codons 844\u2013848. Am J Hum Genet 102, 69\u201387 (2018).","journal-title":"Am J Hum Genet"},{"key":"7318_CR45","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.704639","volume":"12","author":"W Wang","year":"2021","unstructured":"Wang, W. et al. Impacts of NF1 Gene Mutations and Genetic Modifiers in Neurofibromatosis Type 1. Front. Neurol. 12, 704639 (2021).","journal-title":"Front. Neurol."},{"key":"7318_CR46","doi-asserted-by":"crossref","unstructured":"Scala M, Schiavetti I, Madia F, Chelleri C, Piccolo G et al. Genotype-Phenotype Correlations in Neurofibromatosis Type 1: A Single-Center Cohort Study. Cancers 2021; 13.","DOI":"10.3390\/cancers13081879"},{"key":"7318_CR47","doi-asserted-by":"crossref","unstructured":"Chen Y, Fu Y, Koczkowska M, Callens T, Gomes A et al. Genotype-Phenotype Correlation in Neurofibromatosis Type 1: Evidence for a Mild Phenotype Associated with Splicing Variants Leading to In-Frame Skipping of NF1 Exon 24 [19a]. Cancers 2024; 16.","DOI":"10.3390\/cancers16132406"},{"key":"7318_CR48","doi-asserted-by":"publisher","first-page":"3124","DOI":"10.1074\/jbc.M115.703710","volume":"291","author":"Y Hirata","year":"2016","unstructured":"Hirata, Y. et al. Interaction between a domain of the negative regulator of the Ras-ERK pathway, SPRED1 protein, and the GTPase-activating protein-related domain of neurofibromin is implicated in legius syndrome and neurofibromatosis type 1. J. Biol. Chem. 291, 3124\u20133134 (2016).","journal-title":"J. Biol. Chem."},{"key":"7318_CR49","doi-asserted-by":"publisher","DOI":"10.1002\/pro.70042","volume":"34","author":"L Xu","year":"2025","unstructured":"Xu, L., Jang, H. & Nussinov, R. Allosteric modulation of NF1 GAP: Differential distributions of catalytically competent populations in loss-of-function and gain-of-function mutants. Protein Sci. 34, e70042 (2025).","journal-title":"Protein Sci."},{"key":"7318_CR50","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1038\/sj.jid.5701095","volume":"128","author":"S De Schepper","year":"2008","unstructured":"De Schepper, S. et al. Somatic mutation analysis in NF1 cafe au lait spots reveals two NF1 hits in the melanocytes. J. Invest. Dermatol. 128, 1050\u20131053 (2008).","journal-title":"J. Invest. Dermatol."},{"key":"7318_CR51","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1136\/bjophthalmol-2017-311305","volume":"102","author":"K Falzon","year":"2018","unstructured":"Falzon, K., Drimtzias, E., Picton, S. & Simmons, I. Visual outcomes after chemotherapy for optic pathway glioma in children with and without neurofibromatosis type 1: results of the International Society of Paediatric Oncology (SIOP) Low-Grade Glioma 2004 trial UK cohort. Br. J. Ophthalmol. 102, 1367\u20131371 (2018).","journal-title":"Br. J. Ophthalmol."},{"key":"7318_CR52","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1215\/15228517-2007-031","volume":"9","author":"P Dalla Via","year":"2007","unstructured":"Dalla Via, P. et al. Visual outcome of a cohort of children with neurofibromatosis type 1 and optic pathway glioma followed by a pediatric neuro-oncology program. Neuro. Oncol 9, 430\u2013437 (2007).","journal-title":"Neuro. Oncol"},{"key":"7318_CR53","doi-asserted-by":"publisher","first-page":"3691","DOI":"10.1200\/JCO.2008.21.2738","volume":"27","author":"TE Merchant","year":"2009","unstructured":"Merchant, T. E., Conklin, H. M., Wu, S., Lustig, R. H. & Xiong, X. Late effects of conformal radiation therapy for pediatric patients with low-grade glioma: prospective evaluation of cognitive, endocrine, and hearing deficits. J. Clin, Oncol, 27, 3691\u20133697 (2009).","journal-title":"J. Clin, Oncol,"},{"key":"7318_CR54","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1200\/JCO.2005.03.8349","volume":"24","author":"S Sharif","year":"2006","unstructured":"Sharif, S. et al. Second primary tumors in neurofibromatosis 1 patients treated for optic glioma: substantial risks after radiotherapy. J. Clin. Oncol. 24, 2570\u20132575 (2006).","journal-title":"J. Clin. Oncol."},{"key":"7318_CR55","doi-asserted-by":"publisher","first-page":"3537","DOI":"10.1200\/JCO.2016.68.1585","volume":"34","author":"A Lassaletta","year":"2016","unstructured":"Lassaletta, A. et al. Phase II weekly vinblastine for chemotherapy-na\u00efve children with progressive low-grade glioma: A Canadian pediatric brain tumor consortium study. J. Clin. Oncol. 34, 3537\u20133543 (2016).","journal-title":"J. Clin. Oncol."},{"key":"7318_CR56","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.28833","volume":"68","author":"NJ Ullrich","year":"2021","unstructured":"Ullrich, N. J. et al. Visual outcomes following everolimus targeted therapy for neurofibromatosis type 1-associated optic pathway gliomas in children. Pediatr. Blood Cancer 68, e28833 (2021).","journal-title":"Pediatr. Blood Cancer"},{"key":"7318_CR57","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1093\/neuonc\/noaa071","volume":"22","author":"NJ Ullrich","year":"2020","unstructured":"Ullrich, N. J. et al. A phase II study of continuous oral mTOR inhibitor everolimus for recurrent, radiographic-progressive neurofibromatosis type 1-associated pediatric low-grade glioma: a Neurofibromatosis Clinical Trials Consortium study. Neuro Oncol. 22, 1527\u20131535 (2020).","journal-title":"Neuro Oncol."},{"key":"7318_CR58","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1016\/j.jid.2018.09.016","volume":"139","author":"O Zehou","year":"2019","unstructured":"Zehou, O. et al. Absence of efficacy of everolimus in neurofibromatosis 1-related plexiform neurofibromas: Results from a phase 2a trial. J. Invest. Dermatol. 139, 718\u2013720 (2019).","journal-title":"J. Invest. Dermatol."},{"key":"7318_CR59","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1016\/S1470-2045(12)70414-X","volume":"13","author":"KA Robertson","year":"2012","unstructured":"Robertson, K. A. et al. Imatinib mesylate for plexiform neurofibromas in patients with neurofibromatosis type 1: a phase 2 trial. Lancet Oncol. 13, 1218\u20131224 (2012).","journal-title":"Lancet Oncol."},{"key":"7318_CR60","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1038\/s41591-020-01193-6","volume":"27","author":"MJ Fisher","year":"2021","unstructured":"Fisher, M. J. et al. Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: A phase 2 trial. Nat Med 27, 165\u2013173 (2021).","journal-title":"Nat Med"},{"key":"7318_CR61","doi-asserted-by":"publisher","first-page":"6112","DOI":"10.1158\/1078-0432.CCR-20-1696","volume":"26","author":"LH Boal","year":"2020","unstructured":"Boal, L. H. et al. Pediatric PK\/PD phase I trial of pexidartinib in relapsed and refractory leukemias and solid tumors Including neurofibromatosis type I-related plexiform neurofibromas. Clin. Cancer Res. 26, 6112\u20136121 (2020).","journal-title":"Clin. Cancer Res."},{"key":"7318_CR62","doi-asserted-by":"publisher","first-page":"S91","DOI":"10.1212\/WNL.0000000000012436","volume":"97","author":"C Bettegowda","year":"2021","unstructured":"Bettegowda, C. et al. Genotype-phenotype correlations in neurofibromatosis and their potential clinical use. Neurology 97, S91\u2013S98 (2021).","journal-title":"Neurology"},{"key":"7318_CR63","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1093\/neuonc\/nou140","volume":"17","author":"SA Danielsen","year":"2015","unstructured":"Danielsen, S. A. et al. Methylated RASSF1A in malignant peripheral nerve sheath tumors identifies neurofibromatosis type 1 patients with inferior prognosis. Neuro Oncol 17, 63\u201369 (2015).","journal-title":"Neuro Oncol"},{"key":"7318_CR64","doi-asserted-by":"publisher","first-page":"100","DOI":"10.2174\/1566523220666200806111451","volume":"20","author":"XW Cui","year":"2020","unstructured":"Cui, X. W., Ren, J. Y., Gu, Y. H., Li, Q. F. & Wang, Z. C. NF1, neurofibromin and gene therapy: Prospects of next-generation therapy. Curr. Gene. Ther. 20, 100\u2013108 (2020).","journal-title":"Curr. Gene. Ther."},{"key":"7318_CR65","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/s41434-019-0080-9","volume":"26","author":"RY Bai","year":"2019","unstructured":"Bai, R. Y. et al. Feasibility of using NF1-GRD and AAV for gene replacement therapy in NF1-associated tumors. Gene. Ther. 26, 277\u2013286 (2019).","journal-title":"Gene. Ther."},{"key":"7318_CR66","doi-asserted-by":"publisher","first-page":"2100040","DOI":"10.1002\/adtp.202100040","volume":"4","author":"A Shahryari","year":"2021","unstructured":"Shahryari, A., Burtscher, I., Nazari, Z. & Lickert, H. Engineering gene therapy: Advances and barriers. Adv. Ther. 4, 2100040 (2021).","journal-title":"Adv. Ther."},{"key":"7318_CR67","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtn.2025.102475","volume":"36","author":"AK O'Donohue","year":"2025","unstructured":"O\u2019Donohue, A. K. et al. The evolving landscape of NF gene therapy: Hurdles and opportunities. Mol. Ther. Nucleic Acids 36, 102475 (2025).","journal-title":"Mol. Ther. Nucleic Acids"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-07318-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-07318-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-07318-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,5]],"date-time":"2025-07-05T04:03:06Z","timestamp":1751688186000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-07318-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,5]]},"references-count":67,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["7318"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-07318-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,5]]},"assertion":[{"value":"27 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Medical Ethics Committee of Henan Provincial People\u2019s Hospital (No.134 of 2019).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all individual participants included in the study. For the participants under 18, written informed consent was obtained from their parents. All participants requested anonymity.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}],"article-number":"24008"}}